Our Mission

Our Mission

Our Mission

Related Pages

  • The Challenge

    Due to demographic trends, our health care system is facing major challenges. Individualized medicine, which is tailored to people’s needs, offers new opportunities for more effective, well-tolerated and economically sustainable treatments for serious diseases. Personalized medicine has the potential to transform medical treatment as the mechanisms of disease and treatment become better understood. Ci3 promotes medical strategies which harness the immune system to treat serious illnesses like cancer, autoimmune diseases and infections. With the help of its extensive network of excellence, Ci3 is taking on the challenges facing the health care system.

  • Our Vision

    Our vision is to bring together the outstanding expertise in the Rhine-Main cluster region with regard to drugs, therapeutic approaches and diagnostics in the field of individualized immune intervention and to establish the region as a global leader. Ci3’s ambitious – and achievable – goal is to provide long-term benefits for all health care stakeholders (patients, payers, health care providers and manufacturers) by supporting both the innovative products developed in the cluster as well as the relationships among the cluster’s players. Ci3’s core objective is to promote both national and international advancement of individualized immunotherapies.

  • Our Strategy

    In order to exploit its high potential for innovation and growth, Ci3 is pursuing a five-point strategy:

    1. We are focusing on product sectors, specifically on targeted and effective immunotherapies with few side effects protected by patents and based on biomarkers in indications in which there is both a high unmet medical need and broad market potential (i.e. oncology, autoimmune and infectious diseases).
    2. We are fostering unbroken product development paths characterized by regional co-operations. These range from the identification of targets to research into mechanisms as well as to the development and manufacturing of lead substances, all the way to preclinical and clinical testing, and finally to marketing approval and commercialization. We intend to do all of this while creating collaborations among partners based on their respective strengths.
    3. We are securing excellent technical and management personnel over the long-term through appropriate incentives for top performers and through multidisciplinary training programs of academic institutions and industry.
    4. We are building a sustainable, results-oriented model for value creation, funding and growth with concerted efforts at innovation across all sectors of the health care industry.
    5. We are strengthening the cluster through the regular involvement of experts and key opinion leaders from academia, business, government, educational institutions, regulatory authorities and the health care sector.
  • Our Expertise

    Ci3 is located in a region with one of Europe’s longest and most successful histories in pharmaceutical innovation. The region boasts numerous outstanding partners including large companies, small- and medium-sized enterprises and academic institutions representing many different sectors. These mirror the entire value chain of pharmaceutical product development. Immunological expertise in the Ci3-region has evolved over many decades. In addition to providing the means for the targeted and efficient bench-to-bedside development of immune diagnostics and therapeutics across the entire value chain, concentrating transdisciplinary expertise locally enables the "reverse translation" of clinical findings back into research and development (for example to understand and overcome drug resistance).

  • Integrated product categories of the cluster

  • Opportunities in a changing health care system

    In the light of demographic change and the spread of cancer, autoimmune diseases and infections, the prevention, diagnosis and treatment of common diseases will be among the most important fields of medical activity in the future. The impending transition towards individualized medicine as well as towards stronger preventative approaches will lead to the following key challenges for the entire health care system:

    Drugs need to be biomarker-based, potent and safe.

    Today the cluster is already a global frontrunner in the field of disease-relevant immunological biomarkers. The spectrum of unique disease-specific targets that Ci3 - partners use as diagnostic markers or as starting points for treatment is already one of the world’s most comprehensive. With regard to the development of potent and safe drugs, Ci3 benefits from expertise in the field of immunotherapies which has developed in the region over the course of several decades. If immunotherapies are directed at the correct targets, they are among the most potent, and at the same time among the most well-tolerated modes of action.

    Approved drugs need to become available more readily and in greater numbers.

    The number of approved drugs today is not sufficient to offer all patients appropriate treatment options. Combining different drugs from an extensive "stockpile" offers physicians the opportunity to respond to a patient’s specific needs. Ci3’s partners are working on a variety of immunotherapies and establishing accelerated and effective development strategies. Even today, translational barriers are being overcome through new models of co-operation, the allocation of parts of the value chain to competent network partners and the timely involvement of the regulatory authorities. Within Ci3 there is also a focus on new approaches promoting simple manufacturing processes and short development times. At the same time, concepts for reducing drug manufacturing costs are being pursued which affect, for example, the development of cheaper and more efficient purification matrices for manufacturing active ingredients according to GMP standards.

    The implementation of individualized medicine and preventative approaches requires technological assistance from other disciplines.

    Disruptive innovations most often ensue at the intersections of key disciplines. Important key disciplines for the implementation of individualized therapeutic concepts based on molecular analyses are present in the areas of information technology, high-performance computing and materials science/nanotechnology. In the cluster region, top-level research institutions and SMEs are currently active in these disciplines, resulting in significant synergies and particular added value.

    In drug development, new models of role distribution among the stakeholders involved are required.

    The increasing complexity of drug development and the fact that it is linked to biomarkers which simultaneously need to be validated, necessitates a new dimension of collaboration between the stakeholders involved, such as research institutions, industry, service providers, medical centers, regulatory authorities and payers. Ci3 supports these kinds of project-related co-operations, which are based on the complementarity, quality, proximity and trust that exist among Ci3 and its partners.

    Individualized medicine and prevention are linked to the need for health economic and socio-political action, and require effective training and communication strategies.

    In order to establish an appropriate framework for the implementation of individualized therapies, policy makers need tangible proposals for action. It is also vital to inform the general public about suitable preventive health measures, to create awareness and, with the help of highly visible positive examples, to achieve a greater degree of acceptance in the population. Ci3 is actively engaged in public relations and, in co-operation with partners from the region, offers formats for the targeted recruitment and support of young researchers.